Lawitz, Eric <br/><br/>
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.  [electronic resource] 

 -  Hepatology (Baltimore, Md.)  06 2017 
 - 1803-1809 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1527-3350 
<br/><br/><label>Standard No.: </label>10.1002/hep.29130  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aminoisobutyric Acids<br/>Antiviral Agents--administration & dosage<br/>Carbamates--administration & dosage<br/>Confidence Intervals<br/>Cyclopropanes<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>Genotype<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--drug therapy<br/>Heterocyclic Compounds, 4 or More Rings--administration & dosage<br/>Humans<br/>Lactams, Macrocyclic<br/>Leucine--analogs & derivatives<br/>Macrocyclic Compounds--administration & dosage<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Prospective Studies<br/>Quinoxalines<br/>Ribavirin--administration & dosage<br/>Severity of Illness Index<br/>Sofosbuvir--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Treatment Outcome<br/>Young Adult